Landmark TrialRCTRandomized Controlled Trial
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
New England Journal of Medicine2014IF: 25.4
Talmadge E. King, Williamson Z. Bradford, Socorro Castro-Bernardini, Elizabeth A. Fagan, Ian Glaspole, Marilyn K. Glassberg, Eduard Gorina, Peter Hopkins, David Kardatzke, Lisa Lancaster, David J. Lederer, Steven D. Nathan, Carlos A. Pereira, Steven A. Sahn, Robert Sussman, Jeffrey J. Swigris, Paul W. Noble
Abstract
Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).